US Stock MarketDetailed Quotes

BTAI BioXcel Therapeutics

Watchlist
  • 0.351
  • +0.005+1.36%
Close Dec 24 13:00 ET
  • 0.351
  • 0.0000.00%
Post 17:01 ET
16.98MMarket Cap-0.17P/E (TTM)

BioXcel Therapeutics Key Stats

BioXcel Therapeutics Q3 2024 Earnings Date

Currency:USDNov 14, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
1.33M
214.00K
-1.11M
Miss Est.
+289.33%
-37.24%
-83.88%
EPS
-0.55
-0.32
+0.23
Beat Est.
+68.24%
+81.40%
+41.42%
Buy

Nov 30, 2024

BioXcel Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 1.242M--
Nov 14, 20242024/Q3214.000K / 1.328M--
Aug 6, 20242024/Q21.104M / 1.100M--
May 9, 20242024/Q1582.000K / 632.600K--
Mar 12, 20242023/Q4376.000K / 741.290K--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 1.242M--
Nov 14, 20242024/Q3214.000K / 1.328M--
Aug 6, 20242024/Q21.104M / 1.100M--
May 9, 20242024/Q1582.000K / 632.600K--
Mar 12, 20242023/Q4376.000K / 741.290K--

Unlock Free Earnings Estimates

BioXcel Therapeutics Earnings Reports

Read more

Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Nov 30, 2024

Buy

  • Buy

    66.67%
  • Hold

    33.33%
  • Sell

    0.00%

Price Target

No Data